Standard BioTools Reports Third Quarter 2024 Financial Results
Standard BioTools Inc. (LAB)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) today announced unaudited interim financial results for the third quarter ended September 30, 2024. Recent Highlights: Reported third quarter 2024 revenue of $45 million Ongoing merger cost synergy realization delivered 50% adjusted EBITDA improvement and 35% net loss improvement year-over-yearOperationalized approximately $80 million in merger synergies, expected to be fully realized in 2025, and reinforcing path to adjusted EBITDA break-even in 2026Balance sheet as of September 30, 2024, includes $368 million cash, cash equivalents, restricted cash and short-term investments “Powered by Standard BioTools Business System (SBS), we focused our third quarter efforts on driving commercial execution and enhancing overall operating efficiency. Our team delivered sequential top-line improvement and a significant reduction in spend,” said Michael Egholm,
Show less
Read more
Impact Snapshot
Event Time:
LAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LAB alerts
High impacting Standard BioTools Inc. news events
Weekly update
A roundup of the hottest topics
LAB
News
- Spatial Proteomics Market Projected to Reach USD 264.89 Million by 2032, Driven by a Strong 14.6% CAGR | Polaris Market Research [Yahoo! Finance]Yahoo! Finance
- Standard BioTools Appoints Alex Kim as Chief Financial OfficerGlobeNewswire
- Earnings Release: Here's Why Analysts Cut Their Standard BioTools Inc. (NASDAQ:LAB) Price Target To US$3.17 [Yahoo! Finance]Yahoo! Finance
- Standard BioTools Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Standard BioTools Inc. (NASDAQ: LAB) had its price target lowered by analysts at TD Cowen from $2.75 to $2.50. They now have a "buy" rating on the stock.MarketBeat
LAB
Earnings
- 10/30/24 - Beat
LAB
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- 11/12/24 - Form 144
- LAB's page on the SEC website